Related Experiment Video

Updated: Feb 7, 2026

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.5K

HDACs and HDAC inhibitors in colon cancer

John M Mariadason1

  • 1Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10467, USA. mariada@aecom.yu.edu

Epigenetics
|March 11, 2008
PubMed

Insights

Histone deacetylases (HDACs) regulate colon cell development and cancer. Inhibitors of class I and II HDACs halt colon cancer cell growth, promoting differentiation and apoptosis, suggesting therapeutic potential.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Histone deacetylases (HDACs) are key regulators of colon cell maturation and transformation.
  • Aberrant HDAC expression is linked to colon tumor promotion and progression.
  • Class I and II HDACs play critical roles in colon cancer development.

Purpose of the Study:

  • To review the function and transcriptional mechanisms of class I and II HDACs in colon cell maturation and transformation.
  • To discuss the mechanisms by which HDAC inhibitors (HDACi) induce anti-cancer effects.
  • To explore the role of class III HDAC, Sirt1, in colon cancer.

Main Methods:

  • Literature review of HDAC function in colon cancer.
  • Analysis of transcriptional regulation by HDACs.
  • Examination of HDAC inhibitor mechanisms.

Main Results:

  • HDACs are upregulated in colon tumors and promote tumor growth.
  • HDAC inhibitors induce growth arrest, differentiation, and apoptosis in colon cancer cells.
  • Downregulation of specific HDACs inhibits colon cancer cell growth and tumorigenesis.

Conclusions:

  • Class I and II HDACs are critical regulators in colon cancer.
  • HDAC inhibitors show therapeutic promise for colon cancer treatment.
  • Sirt1's role in colon cancer progression warrants further investigation.

More Related Videos

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS09:20

Simultaneous Measurement of HDAC1 and HDAC6 Activity in HeLa Cells Using UHPLC-MS

Published on: August 10, 2017

9.0K
Efficient iPS Cell Generation from Blood Using Episomes and HDAC Inhibitors08:14

Efficient iPS Cell Generation from Blood Using Episomes and HDAC Inhibitors

Published on: October 28, 2014

13.3K

Related Concept Videos

The Colonization of Land02:22

The Colonization of Land

Changes in the environment of the early Earth drove the evolution of organisms. As prokaryotic organisms in the oceans began to photosynthesize, they produced oxygen. Eventually, oxygen saturated the oceans and entered the air, resulting in an increase in atmospheric oxygen concentration, known as the oxygen revolution approximately 2.3 billion years ago. Therefore, organisms that could use oxygen for cellular respiration had an advantage. More than 1.5 years ago, eukaryotic cells and...
37.7K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
685
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.6K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
615